Gut microbiota differences linked to weight gain and ART in people living with HIV are enterotype specific and minor compared to the large differences linked to sexual behavior by Jan Kehrmann, Alireza Dostmohammadi, Anna-Lena Stumpf, Lara Best, Leah Consten, Hannah Sievert, Felix Maischack, Stefanie Sammet, Sarah Albayrak-Rena, Ann-Kathrin Doerr, Katharina Bohlen, Otgonzul von Velsen, Otgonzul von Velsen, Ivana Kraiselburd, Christina B. Karsten, Farnoush Farahpour, Farnoush Farahpour, Folker Meyer, Stefan Esser, Jan Buer

Subjects: Get full text

Disruption of oncogenic MCL-1-BAX/BAK interaction using integrase inhibitors: insights from a molecular docking and dynamic exploration by Lateef O. Anifowose, Fikayo N. Adegboyega, Oludare M. Ogunyemi, Rukayat O. Akano, Oluwatoyin A. Adeyemo-Salami, Sherif F. Hammad, Mohamed A. Ghazy

Subjects: Get full text

Health Economics Evaluation of Bictegravir/Emtricitabine/Tenofovir for a First-Line Treatment of HIV-1 Infection in China by Wang W, Zhou D, Zhou K, Zhang D, Li H, Zhang H, Jiang X, Wang R, Wang X, Tang W

Subjects: Get full text

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults with HIV/HBV Coinfection: An Open-Label, Single-Arm, Safety and Efficacy Switch Study by Helena Kwakwa, Jacqueline Bran, Julia Ruff, Salma Sharaf, Hyunuk Seung, Sunny Choe, Joel V. Chua

Subjects: Get full text

Associations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional study by Julien De Greef, Khoi Nguyen Nguyen, Matthias Van Hul, Anthony Puel, Jean Cyr Yombi, Bernard Vandercam, Anne Vincent, Laure Elens, Leïla Belkhir, Vincent Haufroid, Patrice D. Cani

Subjects: Get full text

Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Introduced at the First Clinical Visit: A Real-Life Single-Arm Single-center Retrospective Cohort Study by Josip Begovac, Iva Lisičar, Vanja Romih Pintar, Snježana Židovec-Lepej, Ana Planinić, Šime Zekan

Subjects: Get full text

Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up by Massimiliano Lanzafame, Emanuela Lattuada, Andrea Delama, Giovanni Mori, Sandro Vento

Subjects: Get full text

Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV by Eric S. Daar, Chloe Orkin, Paul E. Sax, Debbie Hagins, Anton Pozniak, Kimberly Workowski, Cynthia Brinson, Juan Manuel Tiraboschi, Hui Liu, Chris Deaton, Cal Cohen, Sharline Madera, Jason T. Hindman, Moti Ramgopal

Subjects: Get full text

Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucl... by Collins Iwuji, Laura Waters, Ana Milinkovic, Chloe Orkin, Julie Fox, Frank Post, Nicky Perry, Chloe Bruce, Natalie Dailey, Ye To, Stephen Bremner, Duncan Churchill, Anna Maria Geretti

Subjects: Get full text

Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysisResearch in context by Zhou Fang, Tetiana Povshedna, Rowan Patterson, Erin Ready, Helene C.F. Cote, Melanie C.M. Murray, Elizabeth M. King

Subjects: Get full text

Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide by Aleksandra Berkan-Kawińska, Anna Piekarska, Hanna Berak, Włodzimierz Mazur, Aleksander Garlicki, Magdalena Tudrujek-Zdunek, Beata Lorenc, Dorota Dybowska, Łukasz Socha, Anna Parfieniuk-Kowerda, Robert Flisiak

Subjects: Get full text

Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study by Nicola Squillace, Elena Delfina Ricci, Giancarlo Orofino, Gabriele Forcina, Laura Albini, Barbara Menzaghi, Giuseppe Vittorio De Socio, Stefania Piconi, Paolo Maggi, Giordano Madeddu, Giovanni Francesco Pellicanò, Eleonora Sarchi, Benedetto Maurizio Celesia, Filippo Lagi, Elena Salomoni, Antonio Di Biagio, Paolo Bonfanti

Subjects: Get full text

Successful viral suppression in a two-year-old child with human immunodeficiency virus infection treated with bictegravir/emtricitabine/tenofovir alafenamide by Coskun Ekemen, Asli Arslan, Emine Cigdem Ozer, Selda Erensoy, Zumrut Sahbudak Bal, Gulhadiye Avcu

Subjects: Get full text

Emergence of Bictegravir Resistance in a Treatment-Experienced PWH on Functional Monotherapy and Rapid Replacement by an Ancient Wild-Type Strain Following Transient Treatment Inte... by Pietro B. Faré, Gabriela Ziltener, Judith Bergadà Pijuan, Irene A. Abela, Britta L. Hirsch, Michael Huber, Johannes Nemeth, Huldrych F. Günthard

Subjects: Get full text

Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation inte... by Daniele Armenia, Greta Marchegiani, Daniele Spalletta, Luca Carioti, Alessandro Tavelli, Maria Concetta Bellocchi, Vincenzo Spagnuolo, Valentina Mazzotta, Eugenia Quiros-Roldan, Valeria Bono, Stefania Carrara, Sergio Lo Caputo, Antonella D’Arminio Monforte, Francesca Ceccherini-Silberstein, Stefano Rusconi, Maria Mercedes Santoro

Subjects: Get full text

Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV by Anton Pozniak, Chloe Orkin, Yazdan Yazdanpanah, Axel Baumgarten, Karam Mounzer, Michelle L. D’Antoni, Hailin Huang, Hui Liu, Kristen Andreatta, Laurie A. VanderVeen, Christian Callebaut, Jason T. Hindman, José R. Arribas

Subjects: Get full text

Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational B... by Benoit Trottier, Chia-Jui Yang, Dai Watanabe, Giulia Marchetti, Daniel Elbirt, Eoghan De Barra, Alper Gündüz, Sun Hee Lee, Roger Vogelmann, Olivier Robineau, Chiaw Yee Choy, Marvin Berrevoets, Alison Uriel, David Thorpe, Marion Heinzkill, Andrea Marongiu, Johanna Ramroth, Lisa D’Amato, Josep Mallolas

Subjects: Get full text

Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-rand... by Roberta Gagliardini, Marta Camici, Simone Lanini, Rita Bellagamba, Sandrine Ottou, Maria Maddalena Plazzi, Alessandra Vergori, Valentina Mazzotta, Annalisa Mondi, Marisa Fusto, Jessica Paulicelli, Massimo Tempestilli, Carmela Pinnetti, Elisabetta Grilli, Ilaria Mastrorosa, Federico De Zottis, Giulia Del Duca, Andrea Antinori

Subjects: Get full text

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study by Hernando Knobel, Esperanza Cañas-Ruano, Ana Guelar, Pablo Knobel, Judit Villar-García, Alicia González-Mena, Ceclia Canepa, Itziar Arrieta-Aldea, Augustin Marcos, Agustí Abalat-Torrres, Roberto Güerri-Fernández

Subjects: Get full text

From protease inhibitors to integrase strand transfer inhibitors: the evolution of HIV drug resistance management by HU Zhiliang, YANG Yongfeng

Subjects: Get full text